Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44083 | 1.00 | BCL2L1 (0.47) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL44082 | 1.00 | BCL2L1 (0.47) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29412001 | 1.00 | BCL2L1 (0.47) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22150086 | 0.87 | POLB (0.40) | BCL2L1LMNAGAA | |
| SCHEMBL28905933 | 0.86 | ALOX5 (0.49) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30566711 | 0.86 | ALOX5 (0.49) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4954902 | 0.85 | TAS1R3 (0.50) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27587691 | 0.85 | TAS1R3 (0.50) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5263311 | 0.80 | CYP2A6 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22342498 | 0.79 | MAPT (0.46) | CA12CA2CA14LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464324-B1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING BV (NL) | 2021-04-07 | — | — | EP | claimed |
| US-20200102348-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2020-04-02 | — | — | US | claimed |
| US-10344054-B2 | Angiotensin-1-receptor antagonists | FERRING B.V. (NL) | 2019-07-09 | — | — | US | claimed |
| EP-3464324-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | Ferring B.V. (NL) | 2019-04-10 | — | — | EP | claimed |
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | FERRING B.V. (NL) | 2017-12-07 | — | — | US | claimed |
| WO-2017207760-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2017-12-07 | — | — | WO | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| EP-1025127-A1 | MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES | Wapharm AB (SE) | 2000-08-09 | — | — | EP | claimed |
| WO-1998037097-A1 | MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES | WAPHARM AB (SE) | 1998-08-27 | — | — | WO | claimed |
| US-5753619-A | CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | claimed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | claimed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | claimed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20240117363-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | AGTR1, AGTR2, REN | BCL2L1 4115/4885HDAC3 2542/4885HDAC4 888/4885 |
| US-20200102348-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | BCL2L1 4115/4885HDAC3 2542/4885HDAC4 888/4885 |
| US-10344054-B2 | Angiotensin-1-receptor antagonists | AGTR1, AGTR2, AGT | BCL2L1 4440/4885HDAC3 3311/4885HDAC4 1382/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | BCL2L1 3276/4885HDAC3 962/4885HDAC4 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.